medigraphic.com

2018, Number 5

Next >>

Rev Clin Esc Med 2018; 8 (5)

Tejido adiposo como órgano endocrino: Modelo de morbilidad en el síndrome metabólico entre otros

Morales GF, Jimenez BJ

Language: Spanish
References: 28
Page: 1-6
PDF size: 632.64 Kb.


ABSTRACT

Adipose tissue has initially been considered as an energetic reservoir on which this understanding has been profoundly broadened, giving it increasingly a metabolic, endocrinological and immunological role, mainly due to its correlation in the pathological state to multiple major morbidities of high prevalence and mortality. Being perhaps the cardiovascular pathology the main exponent of mortality in the epidemiological profile of developed countries and of many developing countries, special emphasis is placed on the metabolic syndrome as one of the most relevant morbid translations when studying adiposity excess.


REFERENCES

  1. Lyon CJ Law RE Hsueh WA. Minireview: Adiposity, Inflammation, and Atherogenesis. Endocrinology. junio de 2003;144(6):2195-200.

  2. Coelho M Oliveira T Fernandes R. State of the art paper Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013;2:191-200.

  3. Ahima RS Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab TEM. octubre de 2000;11(8):327-32.

  4. Girard J Lafontan M. Impact of visceral adipose tissue on liver metabolism and insulin resistance. Part II: Visceral adipose tissue production and liver metabolism. Diabetes Metab. noviembre de 2008;34(5):439-45.

  5. Ebadi M Baracos VE Bathe OF Robinson LE Mazurak VC. Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with n-6 fatty acid content. Clin Nutr. diciembre de 2016;35(6):1347-53.

  6. Dixon JB. The effect of obesity on health outcomes. Mol Cell Endocrinol. marzo de 2010;316(2):104-8.

  7. Vague J. The Degree of Masculine Differentiation of Obesities. Am J Clin Nutr. 1 de enero de 1956;4(1):20-34.

  8. Montague CT O’Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes. 1 de junio de 2000;49(6):883-8.

  9. Weiss R Bremer AA Lustig RH. What is metabolic syndrome, and why are children getting it?: Metabolic syndrome in children. Ann N Y Acad Sci. abril de 2013;1281(1):123-40.

  10. Roberts CK Hevener AL Barnard RJ. Metabolic Syndrome and Insulin Resistance: Underlying Causes and Modification by Exercise Training. En: Terjung R, editor. Comprehensive Physiology [Internet]. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2013 [citado 5 de junio de 2018]. Disponible en: http://doi. wiley.com/10.1002/cphy.c110062

  11. Ford ES Giles WH Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 16 de enero de 2002;287(3):356-9.

  12. Crepaldi G Maggi C.S. El síndrome metabólico: Un contexto historico. Diabetes Voice. 51(1):8-10.

  13. Park SK Larson JL. The Relationship Between Physical Activity and Metabolic Syndrome in People With Chronic Obstructive Pulmonary Disease. J Cardiovasc Nurs. 2014;29(6):499-507.

  14. Shin J-A Lee J-H Lim S-Y Ha H-S Kwon H-S Park Y-M et al. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Investig. julio de 2013;4(4):334-43.

  15. Yadav D Choi E Ahn SV Baik SK Cho Y zoo Koh SB et al. Incremental Predictive Value of Serum ASTto- ALT Ratio for Incident Metabolic Syndrome: The ARIRANG Study. Lu S-N, editor. PLOS ONE. 25 de agosto de 2016;11(8):e0161304.

  16. Laclaustra Gimeno M Bergua Martínez C Pascual Calleja I Casasnovas Lenguas JA. Síndrome metabólico. Concepto y fisiopatología. Rev Esp Cardiol Supl. enero de 2005;5(4):3D-10D.

  17. Holmes MV Pulit SL Lindgren CM. Genetic and epigenetic studies of adiposity and cardiometabolic disease. Genome Med [Internet]. diciembre de 2017 [citado 7 de mayo de 2018];9(1). Disponible en: http://genomemedicine.biomedcentral.com/ articles/10.1186/s13073-017-0474-5

  18. Eckel RH Grundy SM Zimmet PZ. The metabolic syndrome. The Lancet. abril de 2005;365(9468):1415-28.

  19. Martínez R G Alonso K R Novik A V. Síndrome metabólico: Bases clínicas y fisiopatológicas para un enfoque terapéutico racional. Rev Médica Chile [Internet]. mayo de 2009 [citado 5 de junio de 2018];137(5). Disponible en: http://www.scielo. cl/scielo.php?script=sci_arttext&pid=S0034- 98872009000500014&lng=en&nrm=iso&tlng=en

  20. Yamagishi K Iso H. The criteria for metabolic syndrome and the national health screening and education system in Japan. Epidemiol Health. 6 de enero de 2017;39:e2017003.

  21. Alberti KGMM Eckel RH Grundy SM Zimmet PZ Cleeman JI Donato KA et al. Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 20 de octubre de 2009;120(16):1640-5.

  22. Garvey WT Mechanick JI Brett EM Garber AJ Hurley DL Jastreboff AM et al. American association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. julio de 2016;22(Supplement 3):1-203.

  23. Schmid D Ricci C Behrens G Leitzmann MF. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis: Adiposity and thyroid cancer. Obes Rev. diciembre de 2015;16(12):1042-54.

  24. Kyrgiou M Kalliala I Markozannes G Gunter MJ Paraskevaidis E Gabra H et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 28 de febrero de 2017;j477.

  25. Ebadi M Martin L Ghosh S Field CJ Lehner R Baracos VE et al. Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer. 27 de junio de 2017;117(1):148-55.

  26. Wong C Marwick TH. Obesity cardiomyopathy: diagnosis and therapeutic implications. Nat Clin Pract Cardiovasc Med. septiembre de 2007;4(9):480-90.

  27. Arcaro G Zamboni M Rossi L Turcato E Covi G Armellini F et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int J Obes Relat Metab Disord J Int Assoc Study Obes. septiembre de 1999;23(9):936-42.

  28. Rivers JP Powell-Wiley TM Dey AK Rodante JA Chung JH Joshi AA et al. Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by 18 F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study. JACC Cardiovasc Imaging. febrero de 2018;11(2):349-57.




2020     |     www.medigraphic.com